Human medicines European public assessment report (EPAR): Cimzia, certolizumab pegol, Arthritis, Rheumatoid, Date of authorisation: 01/10/2009, Revision: 24, Status: Authorised

Case Medical Research ◽

10.31525/cmr-b07ad0 ◽

2019 ◽

Author(s):

Keyword(s):

Certolizumab Pegol ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Arthritis Rheumatoid

Download Full-text

Human medicines European public assessment report (EPAR): Cimzia, certolizumab pegol, Arthritis, Rheumatoid, Date of authorisation: 01/10/2009, Revision: 25, Status: Authorised

Case Medical Research ◽

10.31525/cmr-b05123 ◽

2019 ◽

Author(s):

Keyword(s):

Certolizumab Pegol ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Arthritis Rheumatoid

Download Full-text

Human medicines European public assessment report (EPAR): Simponi, golimumab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Arthritis, Rheumatoid, Date of authorisation: 01/10/2009, Revision: 33, Status: Authorised

Case Medical Research ◽

10.31525/cmr-3996ca ◽

2019 ◽

Author(s):

Keyword(s):

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Colitis Ulcerative ◽

Spondylitis Ankylosing ◽

Arthritis Rheumatoid

Download Full-text

Human medicines European public assessment report (EPAR): Riximyo, rituximab, Lymphoma, Non-Hodgkin,Arthritis, Rheumatoid,Microscopic Polyangiitis,Wegener Granulomatosis, Date of authorisation: 15/06/2017, Revision: 3, Status: Authorised

Case Medical Research ◽

10.31525/cmr-16d629c ◽

2019 ◽

Author(s):

Keyword(s):

Microscopic Polyangiitis ◽

Wegener Granulomatosis ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Arthritis Rheumatoid

Download Full-text

Human medicines European public assessment report (EPAR): Erelzi, etanercept, Arthritis, Psoriatic,Psoriasis,Arthritis, Juvenile Rheumatoid,Arthritis, Rheumatoid,Spondylitis, Ankylosing, Date of authorisation: 23/06/2017, Revision: 4, Status: Authorised

Case Medical Research ◽

10.31525/cmr-2115716 ◽

2019 ◽

Author(s):

Keyword(s):

Rheumatoid Arthritis ◽

Juvenile Rheumatoid Arthritis ◽

Assessment Report ◽

Psoriasis Arthritis ◽

European Public ◽

European Public Assessment Report ◽

Spondylitis Ankylosing ◽

Arthritis Rheumatoid

Download Full-text

Human medicines European public assessment report (EPAR): Erelzi, etanercept, Arthritis, Psoriatic,Psoriasis,Arthritis, Juvenile Rheumatoid,Arthritis, Rheumatoid,Spondylitis, Ankylosing, Date of authorisation: 23/06/2017, Revision: 4, Status: Authorised

Case Medical Research ◽

10.31525/cmr-208eb0e ◽

2019 ◽

Author(s):

Keyword(s):

Rheumatoid Arthritis ◽

Juvenile Rheumatoid Arthritis ◽

Assessment Report ◽

Psoriasis Arthritis ◽

European Public ◽

European Public Assessment Report ◽

Spondylitis Ankylosing ◽

Arthritis Rheumatoid

Download Full-text

Human medicines European public assessment report (EPAR): Xeljanz, tofacitinib, Arthritis, Rheumatoid, Date of authorisation: 21/03/2017, Date of refusal: 25/04/2013, Revision: 6, Status: Authorised

Case Medical Research ◽

10.31525/cmr-4ac543 ◽

2018 ◽

Author(s):

Keyword(s):

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Arthritis Rheumatoid

Download Full-text

Human medicines European public assessment report (EPAR): Leflunomide ratiopharm, leflunomide, Arthritis, Rheumatoid, Date of authorisation: 28/11/2010, Revision: 13, Status: Authorised

Case Medical Research ◽

10.31525/cmr-46ca7b ◽

2018 ◽

Author(s):

Keyword(s):

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Arthritis Rheumatoid

Download Full-text

Human medicines European public assessment report (EPAR): Olumiant, baricitinib, Arthritis, Rheumatoid, Date of authorisation: 13/02/2017, Revision: 5, Status: Authorised

Case Medical Research ◽

10.31525/cmr-46ca6e ◽

2018 ◽

Author(s):

Keyword(s):

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Arthritis Rheumatoid

Download Full-text

Human medicines European public assessment report (EPAR): Idacio, adalimumab, Arthritis, Rheumatoid,Arthritis, Juvenile Rheumatoid,Psoriasis,Arthritis, Psoriatic,Spondylitis, Ankylosing,Uveitis,Hidradenitis Suppurativa,Colitis, Ulcerative,Crohn Disease, Date of authorisation: 02/04/2019, Status: Authorised

Case Medical Research ◽

10.31525/cmr-105efa3 ◽

2019 ◽

Author(s):

Keyword(s):

Rheumatoid Arthritis ◽

Crohn Disease ◽

Hidradenitis Suppurativa ◽

Assessment Report ◽

Psoriasis Arthritis ◽

European Public ◽

European Public Assessment Report ◽

Colitis Ulcerative ◽

Spondylitis Ankylosing ◽

Arthritis Rheumatoid

Download Full-text

Human medicines European public assessment report (EPAR): Cyltezo, adalimumab, Hidradenitis Suppurativa,Arthritis, Psoriatic,Psoriasis,Crohn Disease,Arthritis, Juvenile Rheumatoid,Uveitis,Arthritis, Rheumatoid,Colitis, Ulcerative,Spondylitis, Ankylosing, Date of authorisation: 10/11/2017, Revision: 2, Status: Withdrawn

Case Medical Research ◽

10.31525/cmr-39974b ◽

2019 ◽

Author(s):

Keyword(s):

Crohn Disease ◽

Hidradenitis Suppurativa ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Colitis Ulcerative ◽

Spondylitis Ankylosing ◽

Arthritis Rheumatoid

Download Full-text